Community Bank & Trust Waco Texas Purchases 110 Shares of Johnson & Johnson $JNJ

Community Bank & Trust Waco Texas increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,722 shares of the company’s stock after buying an additional 110 shares during the period. Johnson & Johnson accounts for approximately 1.9% of Community Bank & Trust Waco Texas’ holdings, making the stock its 14th biggest position. Community Bank & Trust Waco Texas’ holdings in Johnson & Johnson were worth $8,359,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Nuveen LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at $1,369,188,000. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Pacer Advisors Inc. boosted its holdings in Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $401,420,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.3%

Shares of JNJ stock opened at $185.99 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $186.56. The company has a market capitalization of $447.92 billion, a P/E ratio of 19.89, a P/E/G ratio of 2.36 and a beta of 0.40. The firm has a 50-day moving average price of $175.45 and a 200 day moving average price of $162.51. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm posted $2.82 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.